Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cloxacillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 5/20 | 0.82 |
| ▸ | HPGD | P15428 | 3/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.70 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cloxacillin SCHEMBL41014 | 0.99 | ABCB11 (0.98) | ABCB11LMNAHPGDCYP1A2SLCO1B3 | |
| Cloxacillin SCHEMBL8728823 | 0.98 | ABCB11 (1.00) | ABCB11LMNAHPGDCYP1A2SLCO1B3 | |
| Cloxacillin SCHEMBL11404577 | 0.98 | ABCB11 (1.00) | ABCB11LMNAHPGDCYP1A2SLCO1B3 | |
| Cloxacillin SCHEMBL1625107 | 0.98 | ABCB11 (1.00) | ABCB11LMNAHPGDCYP1A2SLCO1B3 | |
| Cloxacillin SCHEMBL11404582 | 0.98 | ABCB11 (1.00) | ABCB11LMNAHPGDCYP1A2SLCO1B3 | |
| Cloxacillin SCHEMBL2953 | 0.98 | ABCB11 (1.00) | ABCB11LMNAHPGDCYP1A2SLCO1B3 | |
| Cloxacillin SCHEMBL31229061 | 0.98 | ABCB11 (1.00) | ABCB11LMNAHPGDCYP1A2SLCO1B3 | |
| Cloxacillin SCHEMBL11404593 | 0.98 | ABCB11 (1.00) | ABCB11LMNAHPGDCYP1A2SLCO1B3 | |
| Cloxacillin SCHEMBL16333855 | 0.98 | ABCB11 (1.00) | ABCB11LMNAHPGDCYP1A2SLCO1B3 | |
| Cloxacillin SCHEMBL28547421 | 0.97 | ABCB11 (0.98) | ABCB11LMNAHPGDCYP1A2SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482789-A2 | PALATABLE ORAL SUSPENSION AND METHOD | Bristol-Myers Squibb Company (US) | 2004-12-08 | — | — | EP | claimed |
| US-20030187019-A1 | Palatable oral suspension and method | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-10-02 | — | — | US | claimed |
| WO-2003077842-A2 | PALATABLE ORAL SUSPENSION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-25 | — | — | WO | claimed |
| US-11492653-B2 | Methods and kits for detecting antibiotic-inactivating factors | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3669019-A1 | METHODS AND KITS FOR DETECTING ANTIBIOTIC-INACTIVATING FACTORS | University of Louisville Research Foundation, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200172953-A1 | METHODS AND KITS FOR DETECTING ANTIBIOTIC-INACTIVATING FACTORS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2020-06-04 | — | — | US | disclosed |
| US-7175856-B2 | Palatable oral suspension and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1482789-A2 | PALATABLE ORAL SUSPENSION AND METHOD | Bristol-Myers Squibb Company (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030187019-A1 | Palatable oral suspension and method | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| WO-2003077842-A2 | PALATABLE ORAL SUSPENSION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-0273156-A2 | Method for producing pure crystalline products | Bonfanti, Giovanni (IT) | 1988-07-06 | — | — | EP | disclosed |
| US-4272438-A | SILYLATING, ACYLATION | GLAXO GROUP LIMITED (GB) | 1981-06-09 | — | — | US | disclosed |
| US-4182709-A | Manufacture of semi-synthetic penicillin antibiotics | GLAXO GROUP LIMITED (GB) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187019-A1 | Palatable oral suspension and method | TAS2R20, TAS2R60, TAS2R30 | ABCB11 1843/4885LMNA 150/4885HPGD 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.